Yamada S, Yamauchi K, Hisatomi S, Annoh N, Tanaka M
Institute of Brain Diseases, Kurume University School of Medicine, 67 Asahi Machi, 830-0011, Kurume, Japan.
Eur J Pharmacol. 2000 Aug 25;402(3):251-4. doi: 10.1016/s0014-2999(00)00498-2.
To evaluate the antipsychotic property of a sigma(1) receptor ligand, (R)-(+)-1-(4-chlorophenyl)-3-¿4-(2-methoxyethyl)piperazin-1-yl¿ methyl-2-pyrrolidinone-L-tartrate (MS-377), an antagonistic effect of MS-377 on the disruption of prepulse inhibition (PPI) of the acoustic startle by apomorphine or phencyclidine (PCP) was investigated in rats. MS-377 antagonized the PCP-induced disruption of PPI. The ED(50) value of MS-377 for this effect was 0.66 mg/kg. In contrast, apomorphine-induced disruption of PPI was not attenuated by MS-377. These data indicate that the PCP-induced disruption of PPI in rats would be, at least partially, mediated by sigma receptors and MS-377 could be a novel anti-psychotic agent with clinical efficacy for the sensorimotor-gating deficit in schizophrenia.
为评估σ1受体配体(R)-(+)-1-(4-氯苯基)-3-[4-(2-甲氧基乙基)哌嗪-1-基]甲基-2-吡咯烷酮-L-酒石酸盐(MS-377)的抗精神病特性,研究了MS-377对阿扑吗啡或苯环己哌啶(PCP)所致大鼠听觉惊跳前脉冲抑制(PPI)破坏的拮抗作用。MS-377拮抗PCP诱导的PPI破坏。此效应的MS-377的半数有效剂量(ED50)值为0.66 mg/kg。相反,MS-377未减弱阿扑吗啡诱导的PPI破坏。这些数据表明,大鼠中PCP诱导的PPI破坏至少部分由σ受体介导,且MS-377可能是一种对精神分裂症感觉运动门控缺陷具有临床疗效的新型抗精神病药物。